KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-08-12
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to explore the clinical utility of several therapies in patients
with advanced cancer.
This is a multi-center, open-label Phase I/Ib study. The study consists of a dose escalation
part, a dose expansion part testing KAZ954 as a single agent or KAZ954 in combination with
PDR001, NZV930 and NIR178. The dose escalation parts will estimate the MTD and/or RD and test
different dosing schedules.
The dose expansion parts of the study will use the MTD/RDE determined in the dose escalation
part to assess the activity, safety and tolerability of the investigational products in
patients with specific types of cancer.
Approximately 135 adult patients with advanced solid tumors will be enrolled.